Literature DB >> 25797393

Chimeric nucleolin aptamer with survivin DNAzyme for cancer cell targeted delivery.

Nithya Subramanian1, Jagat R Kanwar, Balachandran Akilandeswari, Rupinder K Kanwar, Vikas Khetan, Subramanian Krishnakumar.   

Abstract

A chimeric aptamer-DNAzyme conjugate was generated for the first time using a nucleolin aptamer (NCL-APT) and survivin Dz (Sur_Dz) and exhibited the targeted killing of cancer cells. This proof of concept of using an aptamer for the delivery of DNAzyme can be applied to other cancer types to target survivin in cancer cells in a specific manner.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25797393     DOI： 10.1039/c5cc00939a

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  3 in total

1.  Targeting HMGA2 in Retinoblastoma Cells in vitro Using the Aptamer Strategy.

Authors:  Venkatesan Nalini; Perinkulam Ravi Deepa; Rajeswari Raguraman; Vikas Khetan; Maddy Ashwin Reddy; Subramanian Krishnakumar
Journal:  Ocul Oncol Pathol       Date:  2016-07-02

Review 2.  Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective.

Authors:  Somayeh Vandghanooni; Morteza Eskandani; Jaleh Barar; Yadollah Omidi
Journal:  J Mol Med (Berl)       Date:  2018-07-28       Impact factor: 4.599

Review 3.  Aptamers as Modular Components of Therapeutic Nucleic Acid Nanotechnology.

Authors:  Martin Panigaj; M Brittany Johnson; Weina Ke; Jessica McMillan; Ekaterina A Goncharova; Morgan Chandler; Kirill A Afonin
Journal:  ACS Nano       Date:  2019-11-05       Impact factor: 15.881
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.